.

BioPharmaceutical Business Intelligence

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Baxter
Merck
Farmers Insurance
Dow
McKesson
Harvard Business School
Boehringer Ingelheim
AstraZeneca
Express Scripts
McKinsey

Generated: September 24, 2017

DrugPatentWatch Database Preview

Lamivudine - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for lamivudine and what is the scope of lamivudine patent protection?

Lamivudine
is the generic ingredient in six branded drugs marketed by Mylan Pharms Inc, Glaxosmithkline, Apotex, Lupin Ltd, Cipla Ltd, Aurobindo Pharma Ltd, Apotex Inc, Hetero Labs Ltd V, Silarx Pharms Inc, Viiv Hlthcare, Appco Pharma Llc, Eci Pharms Llc, Merck Sharp Dohme, Pharmacare, Hetero Labs Ltd Iii, Strides Pharma, and Teva Pharms, and is included in twenty-nine NDAs. There are seven patents protecting this compound and three Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Lamivudine has ninety-three patent family members in forty-eight countries.

There are twenty-seven drug master file entries for lamivudine. Twenty-five suppliers are listed for this compound. There are fifty tentative approvals for this compound.

Summary for Generic Name: lamivudine

Tradenames:6
Patents:7
Applicants:17
NDAs:29
Drug Master File Entries: see list27
Suppliers / Packagers: see list25
Bulk Api Vendors: see list86
Clinical Trials: see list515
Patent Applications: see list3,382
Therapeutic Class:Antivirals
Formulation / Manufacturing:see details
Drug Prices:see low prices
DailyMed Link:lamivudine at DailyMed

Tentative approvals for LAMIVUDINE

Applicant Application No. Strength Dosage Form
► Subscribe► Subscribe150MG; 300MG; 200MGTABLET; ORAL
► Subscribe► Subscribe150MG; 300MG; 600MGTABLET; ORAL
► Subscribe► Subscribe150MG; 300MG; 300MGTABLET; ORAL
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Merck Sharp Dohme
DUTREBIS
lamivudine; raltegravir potassium
TABLET;ORAL206510-001Feb 6, 2015DISCNNoNo► Subscribe► SubscribeY► Subscribe
Mylan Pharms Inc
LAMIVUDINE
lamivudine
TABLET;ORAL204528-001Mar 4, 2016ABRXNoNo► Subscribe► Subscribe► Subscribe
Viiv Hlthcare
EPIVIR
lamivudine
SOLUTION;ORAL020596-001Nov 17, 1995AARXYesYes► Subscribe► Subscribe► Subscribe
Viiv Hlthcare
COMBIVIR
lamivudine; zidovudine
TABLET;ORAL020857-001Sep 26, 1997ABRXYesYes► Subscribe► Subscribe ► Subscribe
Merck Sharp Dohme
DUTREBIS
lamivudine; raltegravir potassium
TABLET;ORAL206510-001Feb 6, 2015DISCNNoNo► Subscribe► SubscribeY► Subscribe
Merck Sharp Dohme
DUTREBIS
lamivudine; raltegravir potassium
TABLET;ORAL206510-001Feb 6, 2015DISCNNoNo► Subscribe► SubscribeY► Subscribe
Cipla Ltd
LAMIVUDINE
lamivudine
TABLET;ORAL077221-001Mar 3, 2017ABRXNoNo► Subscribe► Subscribe► Subscribe
Viiv Hlthcare
EPIVIR
lamivudine
TABLET;ORAL020564-001Nov 17, 1995ABRXYesNo► Subscribe► Subscribe► Subscribe
Merck Sharp Dohme
DUTREBIS
lamivudine; raltegravir potassium
TABLET;ORAL206510-001Feb 6, 2015DISCNNoNo► Subscribe► SubscribeY► Subscribe
Apotex Inc
LAMIVUDINE
lamivudine
TABLET;ORAL202941-001Jan 2, 2014ABRXNoNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Orange Book Patents for Generic Ingredient: lamivudine

International Patent Family for Ingredient: lamivudine

Country Document Number Estimated Expiration
Estonia9900440► Subscribe
Norway922182► Subscribe
Japan3264937► Subscribe
China1191061► Subscribe
Poland190505► Subscribe
Bulgaria103818► Subscribe
New Zealand337798► Subscribe
Japan2851480► Subscribe
Slovakia125793► Subscribe
Canada2286126► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: LAMIVUDINE

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
80018Netherlands► SubscribePRODUCT NAME: LAMIVUDINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, EN ZIDOVUDINE; REGISTRATION NO/DATE: EU/1/98/058/001-002 19980318
C0020Belgium► SubscribePRODUCT NAME: LAMIVUDINE/ZIDOVUDINE; REGISTRATION NO/DATE: EU/1/98/058/001 19980318
C/GB98/019United Kingdom► SubscribePRODUCT NAME: A COMBINATION COMPRISING LAMIVUDINE, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, AND ZIDOVUDINE; REGISTERED: UK EU/1/98/058/001 19980318; UK EU/1/98/058/002 19980318
C0022France► SubscribePRODUCT NAME: ABACAVIR SULFATE; LAMIVUDINE; REGISTRATION NO/DATE: EU/1/04/298/001 20041217
C/GB96/043United Kingdom► SubscribePRODUCT NAME: LAMIVUDINE, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT; REGISTERED: CH 53662 19960228; CH 53663 19960228; UK EU/1/96/015/001 19960808; UK EU/1/96/015/002 19960808
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Fish and Richardson
US Department of Justice
Citi
Farmers Insurance
Boehringer Ingelheim
Johnson and Johnson
Deloitte
Federal Trade Commission
Baxter
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot